Distillate Intl Fundamental Stability & Value ETF

Saratoga Investment Management Reduced Roche Holdings in Q2

British American Tobacco Completes Share Repurchase

Maple Rock Capital Partners Inc. Acquires a Large Amount of British American Tobacco Shares in Q2

Roche's Innovative Drug Irelasib Included in National Health Insurance Directory

British American Tobacco Earns CDP ‘AAA’ Rating

UBS analyst maintains buy rating on Roche Holding

Roche Obtains CE Mark Certification for Expanding Its Automated Mass Spectrometry Platform

Canadian Natural Resources Announces Mid-Term Note Pricing

Roche's Breast Cancer Drug Giredestrant Shows Significant Reduction in Recurrence Risk in Clinical Trials

Perodua Launches First Homegrown Electric Vehicle QV-E in Malaysia

British American Tobacco Publishes 2025 Pre-Closure Conference Call Transcript

British American Tobacco Lowers 2026 Earnings Forecast

US Bank Securities reiterates buy rating on British American Tobacco

BAT CEO Sees No Negative Impact on US Vaping Market from New Category

British American Tobacco Announces £1.3 Billion Share Repurchase Program

Roche Launches New PCR Test cobas BV/CV for Vaginal Infections

Roche's Gazyva/Gazyvaro Approved by European Commission for Lupus Nephritis Treatment

British American Tobacco Completes Stock Repurchase in 2025 Reducing Total Shares

Roche's Lunsumio® Shows Positive Progress in Lymphoma Treatment with Combination Therapy

Morgan Stanley Raises Magna International Target Price

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

RHHBY

Saratoga Research & Investment Management reduced its holdings in Roche Holding AG by 2.2% in Q2, now owning 1,978,134 shares worth $80.63 million. Roche is the firm's 9th largest holding, accounting for 4.3% of its portfolio. Other hedge funds also adjusted their positions in Roche. Analysts have mixed ratings on Roche, with an average rating of 'Moderate Buy' and a price target of $57.00.

Market Beat

Roche

Saratoga Investment

Saratoga Research & Investment Management Has $80.63 Million Position in Roche Holding AG $RHHBY

Kepler Capital Markets initiated coverage on British American Tobacco (NYSE:BTI) with a "buy" rating. Other analysts have mixed ratings, including "underperform" and "buy". The stock opened at $58.37, with a 52-week range of $34.82 to $59.29. Hedge funds own 16.16% of the stock. British American Tobacco offers various tobacco and nicotine products globally.

British American Tobacco

British American Tobacco (NYSE:BTI) Coverage Initiated by Analysts at Kepler Capital Markets

On December 12, 2025, British American Tobacco completed a share buyback, reducing its total shares to 2,180,630,797, excluding treasury shares.1British American Tobacco (BAT) announced that Holly Keller Koeppel, a Non-Executive Director, will step down from the Audit Committee effective 31 December 2025.2

TradingView

Key facts: British American Tobacco completes share buyback; Koeppel to resign

NGLOY

The FTSE 100 fell on Friday, pressured by a tech-driven selloff in New York and weak UK economic data.ONS data showed the UK economy unexpectedly contracted in the three months to October.British American Tobacco dropped over 3%, while miners Anglo American, Glencore, Rio Tinto and Antofagasta fell 2%, 1.8%, 1.5% and 0.9%, respectively.Oil majors Shell and BP declined 0.7% and 0.9%, and banks Lloyds and NatWest slid around 1%.

Trading Economics

Anglo American

Anglo American plc

Rio Tinto plc

Rio Tinto

FTSE 100 Down on Friday

Maple Rock Capital Partners Inc. acquired 1,346,400 shares of British American Tobacco p.l.c. (NYSE:BTI) in Q2, valued at $63,725,000. This makes up 3.1% of their holdings, ranking as their 11th largest position. Other hedge funds also increased their stakes in BTI. Analysts have mixed ratings on BTI, with a consensus rating of 'Moderate Buy' and an average target price of $51.00.

Maple Rock Capital Partners Inc. Acquires New Position in British American Tobacco p.l.c. $BTI

British American Tobacco PLC :BAT - HOLLY KELLER KOEPPEL, NON-EXECUTIVE DIRECTOR OF COMPANY, WILL STEP DOWN FROM AUDIT COMMITTEE WITH EFFECT FROM 31 DECEMBER 2025.

Reuters

BAT Says Holly Keller Koeppel To Step Down From Audit Committee

British American Tobacco PLC announced the purchase of 132,000 ordinary shares from Goldman Sachs International as part of its buyback program. The shares were bought at prices ranging from 4,358.00p to 4,404.00p, with a volume-weighted average price of 4,378.00p. The company plans to cancel the purchased shares, reducing its ordinary shares in issue to 2,180,630,797, excluding treasury shares. This transaction may affect shareholder notifications under FCA rules.

London Stock Exchange

REG - British Amer.Tobacco - Transaction in Own Shares

British American Tobacco plc (BAT) has achieved a 'Triple A' score from CDP for its transparency and performance in climate change, forests, and water security. This recognition places BAT on CDP's annual 'A' List, reflecting its commitment to environmental best practices.

British American Tobacco Achieves CDP Triple A Score for Environmental Disclosure

CNQ, CVX, and KMI are highlighted as high-yield oil stocks offering over 4% yields and stable cash flow, crucial for income-focused investors in a bearish oil market projected for 2026. With forecasts of Brent and WTI prices falling below $60 per barrel, these large-cap energy companies provide dividend durability and financial stability, making them attractive options for investors seeking consistent income amidst market volatility.

Yahoo Finance

Kinder Morgan Holdco

Canadian Natural Resource

Chevron

3 High-Yield Oil Stocks for Stable Income in a Bearish Market

British American Tobacco PLC announced that Holly Keller Koeppel, a Non-Executive Director, will join Shell plc as a Non-Executive Director effective 1 January 2026.

REG - British Amer.Tobacco - Director Declaration

UBS analyst Matthew Weston maintains a Buy rating on Roche Holding AG with a price target of CHF356.00. Weston, who covers the Healthcare sector, has an average return of 10.1% and a 78.26% success rate. Roche Holding AG has an analyst consensus of Hold, with a price target consensus of $379.64.